Published in Medical Letter on the CDC and FDA, October 25th, 2009
Mimetogen's lead drug candidate for keratoconjunctivitis sicca (dry eye syndrome), MIM-D3, is a small molecule neurotrophin mimetic acting as a potent mucin secretagogue. The company first reported pre-clinical efficacy data at ARVO, Fort Lauderdale, in May 2009 and subsequently...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA